VERSATILE CLINICAL USE OF ROSUVASTATIN: SHOULD ITS LIPID-LOWERING PROPERTIES BE RELIED ON?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper shows both the lipid-lowering and pleiotropic (non-lipid) effects of rosuvastatin and experimental and clinical backgrounds for its use as both mono- and combination therapy in patients with cardiovascular and associated diseases.

Full Text

Restricted Access

References

  1. Гиляревский С.Р., Орлов В.А., Кузьмина И.М. и др. Гиполипидемические эффекты применения интенсивных режимов приема статинов при лечении больных с острым коронарным синдромом: подходы к выбору препарата и его дозы // Кардиология и сердечно-сосудистая хирургия. - 2012; 4: 36-41.
  2. Зубарева М., Рожкова Т., Горнякова Н. и др. Эффективность, безопасность и переносимость терапии розувастатином у больных очень высокого cердечно-cосудистого риска с первичной гиперхолестеринемией. Предварительные результаты исследования «40x40» // Врач. - 2012; 2: 61-5.
  3. Amarenco P., Labreuche J., Lavallee P. et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis // Stroke. -2004; 35: 2902-9.
  4. Barnes P., Celli B. Systemic manifestations and comorbities in COPD // Eur. Respir. J. - 2009; 33: 1165-85.
  5. Birmingham B., Swan S., Puchalski T. et al. Pharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic Haemodialysis // Clin. Drug. Investig. - 2013 (Epub. ahead of print).
  6. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration // Lancet. -1995; 346: 1647-53.
  7. Crouse J. 3rd, Raichlen J., Riley W. et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial // JAMA. - 2007; 297 (12): 1344-53.
  8. Garcia-Rodriguez L., Massó-González E., Wallander M. et al. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care // Pharmacoepidemiol. Drug. Saf. - 2008;17 (10): 943-52. doi: 10.1002/pds.1603.
  9. Germershausen J., Hunt V., Bostedor R. et al. Tissue selectivity of the cholesterol-lowering agentslovastatin, simvastatin and pravastatin in rats in vivo // Biochem. Biophys. Res. Commun. - 1989; 158: 667-75.
  10. Goldstein J., Brown M. Regulation of the mevalonate pathway // Nature. -1990; 343: 425-30.
  11. Horwich T., MacLellan W., Fonarow G. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure // J.Am. CollCardiol. -2004; 43: 642-8.
  12. Kilic U., Bassetti C., Kilic E. et al. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellularregulated kinase-1/-2 // Neuroscience. - 2005; 134: 901-6.
  13. Kjekshus J., Apetrei E., Barrios V. et al. Rosuvastatin in older patients with systolic heart failure // N. Engl. JMed. - 2007; 357: 2248-61.
  14. Kostapanos M., Milionis H., Elisaf M. An overview of the extra-lipid effects of rosuvastatin // J. Cardiovasc. Pharmacol. Ther. - 2008; 13 (3): 157-74. doi: 10.1177/1074248408318628. Epub 2008 May 6.
  15. LaRosa J., Grundy S., Waters D. et al. For the Treating to New Targets (TNT) Investigators.Intensive lipid lowering with atorvastatin in patients with stablecoronary disease // N. Engl. J. Med. - 2005; 352: 1-11.
  16. McKenney J., Jones P., Adamczyk M. et al. STELLAR Study Group. Comparison of the efficacy of rosuvastatinversusatorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial // Curr. Med. Res. Opin. - 2003; 19 (8): 689-98.
  17. McTaggart F. Comparative pharmacology of rosuvastatin // Atheroscler. -2003; 4: 9-14.
  18. Nassief A., Marsh J. Statin therapy for stroke prevention // Stroke. - 2008; 39: 1042-8.
  19. Nissen S., Nicholls S., Sipahi I. et al. Effect of very highintensitystatin therapy on regression of coronary atherosclerosis: the ASTEROID trial // JAMA. -2006; 295 (13): 1556-65.
  20. Node K., Fujita M., Kitakaze M. et al. Short-term statin therapy improves cardiac functionand symptoms in patients with idiopathic dilated cardiomyopathy // Circulation. - 2003; 108: 839-43.
  21. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering // Arterioscler. Thromb. Vasc. Biol. - 2001; 21: 3-5.
  22. Pitt B., Loscalzo J., Monyak J. et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study) // Am. J. Cardiol. - 2012; 109 (9): 1239-46. doi: 10.1016/j. amjcard.2011.12.015. Epub. 2012 Feb 21.
  23. Prinz V., Laufs U., Gertz K. et al. Intravenous rosuvastatin for acute stroke treatment: an animal study // Stroke. - 2008; 39: 433-8.
  24. Rasmussen F., Mikkelsen D., Hancox R. et al. High-sensitive Creactive protein is associated with reduced lung function in adults // Eur. Respir. J. - 2009; 33: 382-8.
  25. Ridker P. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial // Circulation. - 2003; 108: 2292-7.
  26. Ridker P., Cannon C., Morrow D. et al. C-reactive protein levels and outcomes after statin therapy // N. Engl. J. Med. - 2005; 352: 20-8.
  27. Sever P., Poulter N., Wedel H. et al. For the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial // Lancet. - 2003; 361: 1149-58.
  28. Schmidt W., Spiel A., Jilma B. et al. In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model // Pharmacogenet. Genomics. - 2008; 18: 109-20.
  29. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk // Expert. Rev. Cardiovasc. Ther. - 2007; 5: 177-93.
  30. Sironi L., Gianazza E., Gelosa P. et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects // Arterioscler. Thromb. Vasc. Biol. - 2005; 25: 598-603.
  31. Strippoli G., Navaneethan S. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials // BMJ. - 2008; 336: 645-51.
  32. Van Aelst L., D'Souza Schorey C. RhoGTPases and signaling networks // Genes. Dev. - 1997; 11: 2295-322.
  33. Vidt D., Cressman M., Harris S., Pears J. et al. Rosuvastatin-induced arrest in progression of renal disease // Cardiology. - 2004; 102 (1): 52-60. Epub. 2004 Apr. 2.
  34. Wang C., Liu P., Liao J. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results // Trends. Mol. Med. - 2008; 14: 37-44.
  35. Ikeda H., Takajo Y., Murohara T. et al. Platelet-derived nitric oxide and coronary risk factors // Hypertension. - 2000; 35: 904-7.
  36. Kaneider N., Egger P., Dunzendorfer S., Wiedermann C. Rho-GTPase-dependentplateletneutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function // Arterioscler. Thromb. Vasc. Biol. - 2002; 22: 1029-35.
  37. Greenwood J., Steinman L., Zamvil S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation // Nat. Rev. Immunol. -2006; 6: 358-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies